BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 10352473)

  • 1. Serous borderline tumors of the ovary.
    Prat J
    Adv Clin Path; 1997 Apr; 1(2):97-102. PubMed ID: 10352473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
    McKenney JK; Balzer BL; Longacre TA
    Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma.
    Hogg R; Scurry J; Kim SN; Friedlander M; Hacker N
    Gynecol Oncol; 2007 Jul; 106(1):44-51. PubMed ID: 17467045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion.
    Prat J; De Nictolis M
    Am J Surg Pathol; 2002 Sep; 26(9):1111-28. PubMed ID: 12218568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators.
    Seidman JD; Kurman RJ
    Hum Pathol; 2000 May; 31(5):539-57. PubMed ID: 10836293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors.
    Lu KH; Bell DA; Welch WR; Berkowitz RS; Mok SC
    Cancer Res; 1998 Jun; 58(11):2328-30. PubMed ID: 9622067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glomeruloid peritoneal implants in ovarian serous borderline tumours--distinction between invasive and non-invasive implants and pathogenesis.
    Lee ES; Leong AS; Kim IS; Kim YS; Lee JH; Cho HY
    Histopathology; 2009 Nov; 55(5):505-13. PubMed ID: 19912356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ovarian serous borderline tumor: the prognostic relation to the pathologic features and management].
    Zhou XR; Du XG
    Zhonghua Fu Chan Ke Za Zhi; 1994 Oct; 29(10):601-3, 637. PubMed ID: 7712874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical factors and biomarkers in ovarian tumors development.
    Vrabie CD; Petrescu A; Waller M; Dina I
    Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors): pathology, prognosis, and proposed classification.
    McKenney JK; Balzer BL; Longacre TA
    Am J Surg Pathol; 2006 May; 30(5):614-24. PubMed ID: 16699316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathologic findings in eight cases of ovarian serous borderline tumors, three with foci of serous carcinoma, that preceded death or morbidity from invasive carcinoma.
    Lee KR; Castrillon DH; Nucci MR
    Int J Gynecol Pathol; 2001 Oct; 20(4):329-34. PubMed ID: 11603215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants.
    Kane A; Uzan C; Rey A; Gouy S; Camatte S; Pautier P; Lhommé C; Haie-Meder C; Duvillard P; Morice P
    Oncologist; 2009 Jun; 14(6):591-600. PubMed ID: 19487334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Borderline epithelial tumors of the ovary.
    Hart WR
    Mod Pathol; 2005 Feb; 18 Suppl 2():S33-50. PubMed ID: 15761465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnostic difficulties in serous "borderline" tumors of the ovary].
    Vereczkey I; Tóth E; Orosz Z
    Magy Onkol; 2009 Mar; 53(1):23-31. PubMed ID: 19318323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases.
    Seidman JD; Kurman RJ
    Am J Surg Pathol; 1996 Nov; 20(11):1331-45. PubMed ID: 8898837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of peritoneal extensions for the diagnosis and management of serous ovarian borderline tumors].
    Andrei S; Stolnicu S; Rădulescu D; Mocan S; Puşcaşu L
    Rev Med Chir Soc Med Nat Iasi; 2006; 110(3):679-86. PubMed ID: 17571566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of the micropapillary pattern in patients with serous borderline ovarian tumors.
    Chang SJ; Ryu HS; Chang KH; Yoo SC; Yoon JH
    Acta Obstet Gynecol Scand; 2008; 87(4):476-81. PubMed ID: 18382877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.
    Gershenson DM; Deavers M; Diaz S; Tortolero-Luna G; Miller BE; Bast RC; Mills GB; Silva EG
    Clin Cancer Res; 1999 Dec; 5(12):4053-8. PubMed ID: 10632339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.